Related Experiment Video
Updated: Jun 16, 2026
06:44
Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
Published on: September 8, 2017
SNPs in genes coding for ROS metabolism and signalling in association with docetaxel clearance.
H Edvardsen1, P F Brunsvig, H Solvang
1Department of Genetics, Institute of Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway.
The Pharmacogenomics Journal
|February 17, 2010
Summary
Genetic variations influence how patients clear docetaxel, a chemotherapy drug. Identifying specific single-nucleotide polymorphisms (SNPs) could personalize treatment by predicting drug metabolism and improving patient outcomes.
Area of Science:
- Pharmacogenomics
- Oncology
- Molecular Biology
Background:
- Current docetaxel dosing relies on body surface area, neglecting individual patient factors like genetics.
- Genetic variations can significantly impact drug metabolism and clearance, leading to inter-individual variability in treatment response.
- Understanding these genetic influences is crucial for optimizing chemotherapy regimens.
Purpose of the Study:
- To investigate the association between genetic variations, specifically single-nucleotide polymorphisms (SNPs), and the clearance of docetaxel.
- To identify specific SNPs and genes that influence docetaxel metabolism and clearance in patients with non-small cell lung cancer.
Main Methods:
- A two-stage analysis was employed, initially genotyping 583 SNPs in 203 genes in 24 patients.
- Statistical methods including Analysis of Variance (ANOVA), Quantitative Mutual Information Score (QMIS), and Kruskal-Wallis (KW) analysis were used to identify significant associations.
- A second stage involved genotyping 14 candidate SNPs in an additional 9 patients to validate initial findings.
Main Results:
- Multiple SNPs in genes such as EGF, PRDX4, XPC, GSTA4, TGFBR2, and others were found to be associated with docetaxel clearance.
- Haplotype analysis confirmed associations, and statistical tests identified 14 SNPs (in genes like GSTA4, PRDX4, TGFBR2, XPC, CYP2C8, EPHX1, TPMT, etc.) as significantly or borderline significantly associated with clearance.
- Validation in the second stage confirmed 7 of these SNPs, strengthening the hypothesis of their role in docetaxel clearance.
Conclusions:
- Genetic variations, identified through specific SNPs, are significantly associated with docetaxel clearance.
- These findings suggest that pharmacogenetic profiling could lead to personalized docetaxel dosing strategies.
- Further research validating these SNPs may enable more precise and effective chemotherapy treatments for lung cancer patients.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...